% | $
Quotes you view appear here for quick access.

Fibrocell Science, Inc. Message Board

  • intutivetrendseeker intutivetrendseeker Mar 22, 2012 11:01 PM Flag

    Genius Award "Secret Weapon" is Laviv - in April Elle

    Just read the latest Elle at the spa today (Consider the number of spas and salons in the US with Elle magazines out x the number of clients per day each spa reading those magazines)

    Dr Cheryl Karcher featured in cover story on "2012 Genius Awards" for dermatology. Specifies that her "secret weapon" is Laviv.

    Dr. Karcher is an Upper East NYC dermatogist: "the results of Dr. Karcher's research have been published in numerous peer-reviewed scientific journals including The New England Journal of Medicine, The Journal of Investigative Dermatology, and The Journal of the American Academy of Dermatology.

    Dr. Karcher is frequently called upon to offer her expertise to the national media, such as CNN, The CBS Early Show, Allure, Self, Fitness and Cosmopolitan. She is also the consulting dermatologist to the Miss Universe organization."

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • The call on June 21, 2011, that launched "The MOTHER of all FCSC BEAR TRAPS" on the eve of FCSC FDA-approval by -- the famous insider -- "FCSC-laviv-pumper extra-ordinaire" Dr. Mukinaki.

      ******"No matter how you look at the market (Botox or various types of fillers as shown in the above link, page 23), laViv could easily achieve 100K treatments a year in a short few years after they build out their manufacturing capacity. In the first year, the company already stated that they expect to do 5000 treatments (above link, page 31). So, the ramp up rate will be very fast once the FDA gives their approval.

      What that means is that FCSC could expect 25M in revenue in the first year while ramping up to 500M in a short few years. So, what does that mean in terms of stock price?

      It is reasonable to assume that FCSC could be given a valuation at about 15 times revenue in the first year given the quick revenue ramp. The number of fully diluted shares is about 107M so the stock price should be around *3.50$ shortly after approval.*

      When they achieve 500M a year, the valuation multiple could reduce to a more normal five times revenue because the revenue ramp would slow down. Assuming that stock sales to build out manufacturing would bring the number of stocks to about 150M, that would mean a stock price over 15$ in a few years.

      The above, of course, does not account for any label extensions of laViv for acne and burn scars which could be worth far more. All this potential hinges on the FDA approval tomorrow! GLTA.******

      Read more:

      Yo pal, hiding behind your "face dancing: froyfriedman sobriquet"; I am not the only one who lost a cool $100K on that BEAR of a call, eh... mes/mon ami...

      Genius award, eh? You folks can stuff it. Bring back my $100K eh... that would be genius...

      You are so hosed!

    • Blah, blah, blah, blah..blah blah blah...
      All those awards from: Allure, Elle, etc, etc., and a who knows who...
      If this "stuff" was as great as you "pumpers" have been, and will be "hyping" till kingdom come; then tell us how come it hasn't caught fire where it counts, eh?
      Will you please drop the "silly hype" and show us some measurable "pin action".
      Is that too much to ask?
      Spare us the "genius secret award" and all that "b.s", folks want to sniff, as well as, sip the Dom Pérignon and dine on foie gras.

      No moh' promises please -- your idle promises just broils my bacon, eh...


      Above is a good summary of the history of and how laViv works. There are also a few pictures of patients taken two years after treatment. That's not something that any other fillers like Juvederm or Restylane could claim. Their effects wane after a few months to a year at most. laViv lasts years longer and with no side effects except for redness for a few days!